Evidence map›Paper›PMID 30013407›Full record

ArticleOpen access rheumatology : research and reviews2018

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate.

James R O'Dell, Stanley B Cohen, J Carter Thorne, Joel Kremer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open access rheumatology : research and reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

James R O'DellDepartment of Rheumatology, Division of Rheumatology and Immunology, University of Nebraska Medical Center and the Omaha VA, Omaha, NE, USA, jrodell@unmc.edu.
Stanley B CohenDepartment of Internal Medicine, Metroplex Clinical Research Center, University of Texas Southwestern Medical School, Dallas, TX, USA.
J Carter ThorneDivision of Rheumatology, University of Toronto, Southlake Regional Health Centre, Toronto, ON, Canada.
Joel KremerThe Center for Rheumatology, Albany Medical College, Albany, NY, USA.
Center for Rheumatology · USMetroplex Clinical Research Center · USOmaha VA Medical Center · USUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. PATIENTS AND

methodsThis study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort).

resultsA biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort. Concomitant use of MTX and a biologic declined from 74.1% (2009 cohort) to 45.4% (2012 cohort).

conclusionMTX is underused in the treatment of RA in the USA.

Indexed as

biologicclaimsmethotrexatetumor necrosis factor

Identifiers

PMID30013407
PMCPMC6037273
OpenAlexW2810108657

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.